Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Last month (May 2025), Novo announced that the US Food and Drug Administration (FDA) accepted its new drug application (NDA) submission for an investigational once-daily oral formulation of Wegovy (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease
For long-term courses and prevention, capsules are more convenient
This heart-protective effect makes them an important consideration for individuals with diabetes, who are at a higher risk of heart disease
However, we identified that the zDHHCs do not possess high-affinity binding abilities to Nt 7 sequences, as immunoprecipitation of Nt 7 -GFP constructs did not co-precipitate any of the relevant mRFP-zDHHC-KASH constructs (Supplementary Fig
